Alzheimer’s disease (AD) is the most common form of dementia, involving memory loss and a reduction in cognitive abilities. Patients with AD develop multiple abnormal protein structures in their brains that are thought to destroy or damage nerve cells (neurons). One of these structures, the senile plaque, is made up of clumps of beta-amyloid (Aβ) […]Continue Reading ...
Researchers have succeeded in training an artificial intelligence (AI) algorithm to predict the risk of cognitive decline which could result in Alzheimer’s disease (AD) five years later. Image Credit: Atthapon Raksthapu / Shutterstock At present, there is no effective treatment or cure for AD, but a growing volume of evidence suggests that the disease […]Continue Reading ...
The National Institute on Aging (NIA) has awarded scientists at University of California San Diego School of Medicine and San Diego State University (SDSU) with a five-year, $4 million grant to boost the number of Latino and other underrepresented minority researchers studying Alzheimer’s disease (AD) and related dementias afflicting seniors of Latino origins, a demographic […]Continue Reading ...
Finding an effective way to identify people with mild cognitive impairment who are most likely to go on to develop Alzheimer’s disease has eluded researchers for years. But now, a team of researchers led by David Loewenstein, Ph.D., director of the Center for Cognitive Neuroscience and Aging (CNSA) and professor of psychiatry and behavioral sciences […]Continue Reading ...
By Liji Thomas, MDAugust 17, 2018 An intriguing new study has marked the beginning of the answer to a medical mystery: why is it that some people with classic markers for Alzheimer’s Disease never show any signs of dementia throughout their life? Image Credit: SpeedKingz / Shutterstock Alzheimer’s disease (AD) is the most widespread form […]Continue Reading ...
(HealthDay)—Atopic dermatitis (AD) dramatically impacts the quality of life of patients, according to a study published online July 16 in the Annals of Allergy, Asthma & Immunology. Jonathan I. Silverberg, M.D., Ph.D., from Northwestern University in Chicago, and colleagues assessed the patient-burden of AD among 602 U.S. patients. The researchers found that adults with AD […]Continue Reading ...
July 24, 2018 Roche announced today,that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Elecsys® ß-Amyloid (1-42) CSF and Elecsys® Phospho-Tau (181P) CSF. These in vitro diagnostic immunoassays are for the measurement of the ß-Amyloid (1-42) and Phospho-Tau concentrations in cerebrospinal fluid (CSF) in adult patients with cognitive impairment who […]Continue Reading ...
July 20, 2018 Sage Bionetworks announces the launch of the Agora platform (agora.ampadportal.org) an interactive, web-based tool that allows researchers to explore curated genomic analyses of Alzheimer’s Disease (AD), including a list of early candidate target nominations for AD. The analyses accessible through Agora represent the culmination of over five years of research from the […]Continue Reading ...
PET scan of a human brain with Alzheimer’s disease. Credit: public domain Researchers from Boston University School of Medicine, working with scientists across the nation on the Alzheimer’s Disease Sequencing Project (ADSP), have discovered new genes that will further current understanding of the genetic risk factors that predispose people to the development of Alzheimer’s disease […]Continue Reading ...
Sep 24 2018 Cytox, a precision medicine company which today is commercializing polygenic risk scoring (PRS) approaches for assessing genetic risk for developing Alzheimer’s disease (AD) and other neurological diseases, has announced it has expanded its research collaboration with the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) to test new algorithms for […]Continue Reading ...
Screen shot of Jackson Laboratory-Alzheimer’s Association slide: Together we can end Alzheimer’s disease. Credit: The Jackson Laboratory The MODEL-AD Center, an ambitious project to develop and distribute precise mouse models of late-onset Alzheimer’s disease (AD), has released eight new models carrying genetic mutations found in patients. In past decades, most AD researchers had to rely […]Continue Reading ...
August 1, 2018 A new method published in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging constructs networks based on multiple structural features to identify Alzheimer’s disease and mild cognitive impairment Researchers have developed a new method for constructing personal brain networks using multiple structural features to improve the accuracy of diagnosing Alzheimer’s disease (AD) and mild […]Continue Reading ...
July 26, 2018 BIOCRATES’ Technology Enables Research of Host Microbiome Interactions to Investigate Neurodegenerative Diseases BIOCRATES Life Sciences AG, a global leader in targeted metabolomics, reported today the Alzheimer’s Disease Metabolomics Consortium’s (ADMC) new breakthrough in Alzheimer’s research, which connects the Gut-Liver-Brain axis in the development and progression of Alzheimer’s disease (AD). During the Alzheimer’s […]Continue Reading ...
July 23, 2018 The MODEL-AD Center, an ambitious project to develop and distribute precise mouse models of late-onset Alzheimer’s disease (AD), has released eight new models carrying genetic mutations found in patients. In past decades, most AD researchers had to rely on mouse models that carried a genetic mutation associated with the relatively rare, early-onset, […]Continue Reading ...
July 16, 2018 If you had your genome sequenced and the report says you have the APOEε4 mutation, it does not mean you are definitely going to get Alzheimer’s disease. The reason why is complicated. The specific genetic variant known as APOEε4 (the ε4 mutation of Apolipoprotein E) is the greatest genetic risk factor for […]Continue Reading ...
- Drugs approved for breast cancer treatment are effective and well tolerated in men
- EKF introduces new hand-held lactate analyzer for rapid sports performance monitoring
- Researchers identify common genetic connection in lung conditions
- Forbius initiates Phase 2a trial evaluating efficacy, safety of AVID100 in patients with squamous NSCLC
- Immunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer
- New discovery may lead to better treatment options for pancreatic cancer patients
- FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Asthma
- Researchers identify immune culprits linked to inflammation and bone loss in gum disease
- Despite lower risk factors, black men have higher rates of recidivism
- Study finds why pregnant women in mainland China, Hong Kong and Taiwan prefer cesarean delivery
- AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis
- NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors
- Scientists use electron microscope to study chemical transformation in catalytic cross-coupling reaction
- Research offers new hope to men who received childhood cancer treatment
- Adverse Childhood Experiences Tied to Burnout in BSN Students
- High levels of oral disease among elite athletes affecting performance
- Study examines effect of immediate vs delayed pushing during labor on delivery outcomes
- LU-RRTC to spearhead capacity-building efforts for racial and ethnic populations
- Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients
- Organic food may protect against cancers finds study